Currently, there are 1.51B common shares owned by the public and among those 1.51B shares have been available to trade.
The company’s stock has a 5-day price change of 2.12% and -1.31% over the past three months. CX shares are trading -6.21% year to date (YTD), with the 12-month market performance down to -35.33% lower. It has a 12-month low price of $4.89 and touched a high of $8.35 over the same period. CX has an average intraday trading volume of 12.80 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.71%, -11.45%, and -11.10% respectively.
Institutional ownership of Cemex S.A.B. De C.V. ADR (NYSE: CX) shares accounts for 31.31% of the company’s 1.51B shares outstanding.
It has a market capitalization of $8.00B and a beta (3y monthly) value of 1.40. The stock’s trailing 12-month PE ratio is 8.28, while the earnings-per-share (ttm) stands at $0.64. The company has a PEG of 0.68 and a Quick Ratio of 0.58 with the debt-to-equity ratio at 0.68. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.85% over the week and 4.80% over the month.
Analysts forecast that Cemex S.A.B. De C.V. ADR (CX) will achieve an EPS of 0 for the current quarter, 0 for the next quarter and 0.77 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0 while analysts give the company a high EPS estimate of 0. Earnings per share for the fiscal year are expected to increase by 4.79%, and 19.21% over the next financial year. EPS should shrink at an annualized rate of 12.17% over the next five years, compared to 60.47% over the past 5-year period.
RBC Capital Mkts coverage for the Cemex S.A.B. De C.V. ADR (CX) stock in a research note released on December 11, 2024 offered a Underperform rating with a price target of $5. JP Morgan was of a view on October 29, 2024 that the stock is Neutral, while RBC Capital Mkts gave the stock Sector Perform rating on October 08, 2024, issuing a price target of $9- $6.50. JP Morgan on their part issued Overweight rating on August 21, 2024.
